Evidence map›Paper›PMID 30826987›Full record

ReviewCNS drugs2019

Expanding Role of NMDA Receptor Antagonists in the Management of Pain.

Denise Kreutzwiser, Qutaiba A Tawfic

Open access · hybridAbstract readReview
PubMed Publisher
In one paragraph

Review in CNS drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 7 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 7 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Ketamine and other NMDA receptor antagonists for chronic pain.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Neuropathic pain in burn patients - A common problem with little literature: A systematic review.Burns : journal of the International Society for Burn Injuries · 2024
    Pooled it
  4. Pooled it
  5. Infusion Therapy in the Treatment of Neuropathic Pain.Current pain and headache reports · 2022
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Memantine as a pain management strategy post-total knee arthroplasty: a randomized controlled trial.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2026
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Effects ofPain reports · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Methadone for intractable cancer pain associated with pelvic floor lesions: a retrospective analysis of 36 cases.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Denise KreutzwiserPain Management Program, St. Joseph's Hospital, St. Joseph's Health Care London, PO Box 5777, Stn. B., London, ON, N6A 4V2, Canada.
Qutaiba A TawficDepartment of Anesthesia and Perioperative Medicine, London Health Science Centre and Western University, 339 Windermere Road, London, ON, N6A 5A5, Canada. drqutaibaamir@yahoo.com.
London Health Sciences Centre · CASt Joseph's Health Care · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pain management is complex regardless of whether the pain is acute or chronic in nature or non-cancer or cancer related. In addition, relatively few pain pharmacotherapy options with adequate efficacy and safety data currently exist. Consequently, interest in the role of NMDA receptor antagonists as a pharmacological pain management strategy has surfaced. This narrative review provides an overview of the NMDA receptor and elaborates on the pharmacotherapeutic profile and pain management literature findings for the following NMDA receptor antagonists: ketamine, memantine, dextromethorphan, and magnesium. The literature on this topic is characterized by small studies, many of which exhibit methodological flaws. To date, ketamine is the most studied NMDA receptor antagonist for both acute and chronic pain management. Although further research about NMDA receptor antagonists for analgesia is needed and the optimal dosage/administration regimens for these drugs have yet to be determined, ketamine appears to hold the most promise and may be of particular value in the perioperative pain management realm.

Indexed as

Analgesics, OpioidAnimalsHumansPainPain ManagementReceptors, N-Methyl-D-AspartateAnalgesics, OpioidReceptors, N-Methyl-D-Aspartate

Identifiers

PMID30826987
OpenAlexW2920380976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.